Fortress Biotech, Inc. (FBIO)
NASDAQ: FBIO · Real-Time Price · USD
2.760
-0.120 (-4.17%)
At close: Mar 27, 2026, 4:00 PM EDT
2.705
-0.055 (-2.00%)
After-hours: Mar 27, 2026, 7:42 PM EDT
Fortress Biotech Revenue
Fortress Biotech had revenue of $17.63M in the quarter ending September 30, 2025, with 20.52% growth. This brings the company's revenue in the last twelve months to $62.30M, down -0.32% year-over-year. In the year 2024, Fortress Biotech had annual revenue of $57.68M, down -31.76%.
Revenue (ttm)
$62.30M
Revenue Growth
-0.32%
P/S Ratio
1.37
Revenue / Employee
$616,861
Employees
101
Market Cap
85.66M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57.68M | -26.84M | -31.76% |
| Dec 31, 2023 | 84.51M | 8.77M | 11.58% |
| Dec 31, 2022 | 75.74M | 6.95M | 10.11% |
| Dec 31, 2021 | 68.79M | 23.19M | 50.86% |
| Dec 31, 2020 | 45.60M | 8.97M | 24.49% |
| Dec 31, 2019 | 36.63M | 9.75M | 36.26% |
| Dec 31, 2018 | 26.88M | 9.64M | 55.88% |
| Dec 31, 2017 | 17.25M | 11.09M | 180.09% |
| Dec 31, 2016 | 6.16M | 5.29M | 613.44% |
| Dec 31, 2015 | 863.00K | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Gossamer Bio | 48.47M |
| Pyxis Oncology | 13.86M |
| Kazia Therapeutics | 1.27M |
| Seres Therapeutics | 789.00K |
| Spruce Biosciences | 697.00K |
FBIO News
- 4 days ago - Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 11 days ago - Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026 - GlobeNewsWire
- 4 weeks ago - UPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 4 weeks ago - Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million - GlobeNewsWire
- 4 weeks ago - Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease - GlobeNewsWire
- 5 weeks ago - Fortress Biotech: The PRV Catalyst That Could Reprice This Microcap - Seeking Alpha
- 2 months ago - Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States - GlobeNewsWire
- 3 months ago - Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission - GlobeNewsWire